Related Experiment Video
Updated: Jan 8, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Contemporary trends on the kinase inhibitors with special reference to quinoxaline derivatives
Kirti Sharma1, Asim Kumar2, Srikant Bhagat3
1Saraswati Institute of Pharmaceutical Education and Research, Gharuan, Mohali, 140413, Punjab, India.
Abstract:
Nitrogen-containing heterocycles owing to their unique physicochemical properties and biological effects are always of paramount importance for the development of novel class of bioactive molecules or potential lead molecules. Nitrogen containing heterocycles have tremendous potential to be developed as bioactive molecules which could inspired medicinal chemists to devise novel and greener methodologies to access them. Quinoxaline is one such valuable and indispensable scaffold having plethora of biological activities. The chemical structure of quinoxaline comprises a fused benzene and pyrazine ring. The broad spectrum of pharmacological activities of quinoxaline includes "anticancer", "antimicrobial", "antitubercular", "antiviral", "antileprotic" and "hepatoprotective". The current review, encompasses the contemporary advancements in the role of kinase and various quinoxaline based small molecule kinase inhibitors reported between 2009 and 2024 with special emphasis on their emerging mechanisms of action. The current manuscript highlights some of the recent seminal literature reports pertaining to the structural modifications carried out on quinoxaline scaffold to develop a novel anticancer agent having kinase inhibitory activity.
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drugs that Destabilize Microtubules

